secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-09-09T12:33:41+00:00
Accession:  0001867096-26-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris details XP-8121 Phase 3 plan; expects $1-3B peak revenue, launch in 2030
------------------------------------------------------------------------------

- Phase 3 Cornerstone study: 500 patients, 1:1 vs oral levothyroxine, 54 weeks, primary endpoint TSH normal at weeks 48/54.
- Topline results expected late 2028; FDA approval and launch anticipated 2030.
- Peak net revenue potential $1-3 billion for once-weekly subcutaneous levothyroxine.
- Additional studies: pediatric (Capstone), special population (Touchstone), real-world evidence.
- KOL Dr. David Robertson to serve as Cornerstone investigator.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/0001867096-26-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/xers-20260909.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer